153 related articles for article (PubMed ID: 35273730)
41. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
[TBL] [Abstract][Full Text] [Related]
42. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
[TBL] [Abstract][Full Text] [Related]
44. Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment.
Tian N; Wang D; Li X; Xue M; Zheng B
Evid Based Complement Alternat Med; 2022; 2022():5651793. PubMed ID: 35942377
[TBL] [Abstract][Full Text] [Related]
45. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
Harris MB; Gieser P; Goorin AM; Ayala A; Shochat SJ; Ferguson WS; Holbrook T; Link MP
J Clin Oncol; 1998 Nov; 16(11):3641-8. PubMed ID: 9817286
[TBL] [Abstract][Full Text] [Related]
46. Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation.
Savani M; Skubitz KM
J Pediatr Hematol Oncol; 2019 Mar; 41(2):e94-e96. PubMed ID: 30045149
[TBL] [Abstract][Full Text] [Related]
47. Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.
O'Kane GM; Cadoo KA; Walsh EM; Emerson R; Dervan P; O'Keane C; Hurson B; O'Toole G; Dudeney S; Kavanagh E; Eustace S; Carney DN
Clin Sarcoma Res; 2015; 5():17. PubMed ID: 26175892
[TBL] [Abstract][Full Text] [Related]
48. Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.
Marec-Berard P; Laurence V; Occean BV; Ray-Coquard I; Linassier C; Corradini N; Collard O; Chaigneau L; Cupissol D; Kerbrat P; Saada-Bouzid E; Delcambre C; Gouin F; Guillemet C; Jimenez M; Lervat C; Gaspar N; Le Deley MC; Brugieres L; Piperno-Neumann S
J Adolesc Young Adult Oncol; 2020 Apr; 9(2):172-182. PubMed ID: 31702419
[No Abstract] [Full Text] [Related]
49. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
50. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
51. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
[TBL] [Abstract][Full Text] [Related]
52. High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series.
Palmerini E; Setola E; Grignani G; D'Ambrosio L; Comandone A; Righi A; Longhi A; Cesari M; Paioli A; Hakim R; Pierini M; Marchesi E; Vanel D; Pignochino Y; Donati DM; Picci P; Ferrari S
Cells; 2020 Oct; 9(11):. PubMed ID: 33142760
[No Abstract] [Full Text] [Related]
53. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
54. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
55. Metastatic osteosarcoma.
Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
[TBL] [Abstract][Full Text] [Related]
56. [Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report].
Markiewicz K; Zeman K; Kozar A; Gołebiowska-Wawrzyniak M
Med Wieku Rozwoj; 2011; 15(1):25-31. PubMed ID: 21786509
[TBL] [Abstract][Full Text] [Related]
57. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
[TBL] [Abstract][Full Text] [Related]
58. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM; Smeland S; Bielack SS; Bernstein M; Jovic G; Krailo MD; Hook JM; Arndt C; van den Berg H; Brennan B; Brichard B; Brown KLB; Butterfass-Bahloul T; Calaminus G; Daldrup-Link HE; Eriksson M; Gebhardt MC; Gelderblom H; Gerss J; Goldsby R; Goorin A; Gorlick R; Grier HE; Hale JP; Hall KS; Hardes J; Hawkins DS; Helmke K; Hogendoorn PCW; Isakoff MS; Janeway KA; Jürgens H; Kager L; Kühne T; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Meyers PA; Mottl H; Nathrath M; Papai Z; Randall RL; Reichardt P; Renard M; Safwat AA; Schwartz CL; Stevens MCG; Strauss SJ; Teot L; Werner M; Sydes MR; Whelan JS
Lancet Oncol; 2016 Oct; 17(10):1396-1408. PubMed ID: 27569442
[TBL] [Abstract][Full Text] [Related]
59. Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand.
Choeyprasert W; Natesirinilkul R; Charoenkwan P; Sittipreechacharn S
Asian Pac J Cancer Prev; 2013; 14(2):1101-6. PubMed ID: 23621194
[TBL] [Abstract][Full Text] [Related]
60. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
Meazza C; Cefalo G; Massimino M; Daolio P; Pastorino U; Scanagatta P; Morosi C; Podda M; Ferrari A; Terenziani M; Spreafico F; Casanova M; Parafioriti A; Collini P; Gandola L; Bastoni S; Biassoni V; Schiavello E; Chiaravalli S; Puma N; Bergamaschi L; Luksch R
Med Oncol; 2017 Nov; 34(12):191. PubMed ID: 29094224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
